Teva Pharma

Teva Pharm has issued a package of senior, unsecured notes totaling about $4.9 billion in five tranches across three jurisdictions. The offerings include €1 billion (coupon 4.25%, maturity 2033), €500 million (4.625%, 2036), two $1 billion U.S. tranches (5.50% due 2034 and 5.75% due 2037) and $1.2 billion (5.25%, 2032). Teva intends to use the net proceeds together with cash on hand to repay certain existing bonds, to cover fees and expenses, and for general corporate purposes; settlement is planned for around 16 September 2026. » Más en de.investing.com

Teva Pharm reports a clear success in a phase‑2a study of the anti‑interleukin‑15 antibody TEV ’408 for the treatment of celiac disease: the primary endpoint was met and at week 8 the drug showed a statistically significant and clinically meaningful prevention of gluten‑induced intestinal damage with a good tolerability profile. TEV ’408 is also being tested in a phase‑2b study for vitiligo and was developed in collaboration with Royalty Pharma, which has pledged up to USD 500 million for clinical development. The news triggered an approximately 3.3% premarket share price increase and bolsters Teva Pharm’s pipeline story ahead of further corporate milestones. » Más en de.investing.com

Teva Pharm announced a joint commitment with the Trump administration to reduce prices of selected drugs for Medicaid patients and is continuing to negotiate a final agreement called GENEROUS. Planned measures include aligning US Medicaid prices with pricing in developed markets and introducing a most‑favored‑nation clause for future innovations. The company also announced stockpiles of certain active ingredients to support public health and additional investments in US manufacturing capacity; negotiation terms remain confidential. » Más en de.investing.com